Literature DB >> 1261155

Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.

A Karim, J Zagarella, T C Hutsell, M Dooley.   

Abstract

Steady-state plasma levels of canrenone have been examined in 23 healthy men who received repeated doses of spironolactone for 15 days. The dose regimens were 200 mg once a day and 50 mg 4 times a day. With both treatments the steady-state levels were reached after 3 to 4 days. With once-a-day treatment, the maximum and minimum steady-state levels were about 500 and 100 ng/ml, respectively. The minimum levels with treatment 4 times a day were about 200 ng/ml. The post steady-state half-life of canrenone with once-a-day treatment (19.2 +/- 6.57 hr) was longer (p less than 0.01) than the half-life obtained in the 4 times-a-day treatment (12.5 +/- 3.39 hr). The former half-life was similar to the log-linear phase half-life of canrenone in the single-dose studies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261155     DOI: 10.1002/cpt1976192177

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  An LC-MS assay for the screening of cardiovascular medications in human samples.

Authors:  Eduardo Dias; Brian Hachey; Candace McNaughton; Hui Nian; Chang Yu; Brittany Straka; Nancy J Brown; Richard M Caprioli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-08-16       Impact factor: 3.205

2.  Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses.

Authors:  W Krause; C Sack; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.

Authors:  G T McInnes; J R Shelton; I R Harrison; R M Perkins; R F Palmer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Comparison of single and divided daily dose spironolactone in the control of hypertension.

Authors:  G M Bell; L Fananapazir; J L Anderton
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

Review 6.  Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease.

Authors:  Audra Stewart; Luc P Brion; Iris Ambrosio-Perez
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

7.  Spironolactone dose-response relationships in healthy subjects.

Authors:  G T McInnes; R M Perkins; J R Shelton; I R Harrison
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

8.  Use of a bioassay in healthy men to evaluate diuretic-spironolactone combinations.

Authors:  G T McInnes; J R Shelton; R M Perkins; I R Harrison; J M Clarke
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

9.  Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; V Heazlewood
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.